Paclitaxel ⚖️ PAD 🚫 Promise or Peril?

🚨 New Evidence Alert 🚨 The SWEDEPAD 1 & 2 trials + a powerful Lancet commentary have reshaped how we view paclitaxel-coated devices in peripheral artery disease.   👉 No benefit for amputation or quality of life. 👉 A concerning signal for higher 5-year mortality in claudication. 👉 Registry-based RCTs prove invaluable for real-world insights.   ⚖️ Message: Harm may outweigh benefit — time to rethink strategies and explore alternatives like sirolimus.   #PAD #ClinicalTrials #Cardiology #SWEDEPAD 🫀